Adaptive Biotechnologies Corporation (ADPT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Chad M. Robins M.B.A. | Co-Founder, CEO & Chairman | 1.19M | 248.74k | 1974 |
| Ms. Julie Rubinstein | President & COO | 760.46k | -- | 1972 |
| Dr. Harlan S. Robins Ph.D. | Co-Founder & Chief Scientific Officer | 759.61k | -- | 1973 |
| Mr. Kyle Piskel | VP, CFO & Principal Accounting Officer | 375.9k | -- | 1984 |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine | 671.29k | -- | 1974 |
| Mr. Christopher Carlson Ph.D. | Founder | -- | -- | -- |
| Karina Calzadilla | Vice President of Investor Relations | -- | -- | -- |
| Ms. Stacy L. Taylor | Senior VP, General Counsel & Corporate Secretary | -- | -- | 1960 |
| Mr. Francis T. Lo | Chief People Officer | -- | -- | 1981 |
| Ms. Susan Bobulsky | Chief Commercial Officer of MRD | -- | -- | 1982 |
Adaptive Biotechnologies Corporation
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 709
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Corporate Governance
Recent Events
- Apr 09, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 05, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 02, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing